Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Accumulated Expenses for 7 consecutive years, with $29.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 38.19% to $29.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.3 million through Dec 2025, down 38.19% year-over-year, with the annual reading at $29.3 million for FY2025, 38.19% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $29.3 million at Beam Therapeutics, down from $42.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $111.7 million in Q4 2023, with the low at $1.8 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $33.8 million, with a median of $29.8 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 1221.36% in 2022, then crashed 82.79% in 2025.
  • Over 5 years, Accumulated Expenses stood at $11.7 million in 2021, then soared by 328.03% to $49.9 million in 2022, then surged by 123.72% to $111.7 million in 2023, then tumbled by 57.49% to $47.5 million in 2024, then tumbled by 38.19% to $29.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $29.3 million, $42.3 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.